• Je něco špatně v tomto záznamu ?

Association Between Premorbid Beta-Blocker Exposure and Sepsis Outcomes-The Beta-Blockers in European and Australian/American Septic Patients (BEAST) Study

K. Tan, M. Harazim, A. Simpson, YC. Tan, G. Gunawan, KP. Robledo, C. Whitehead, B. Tang, A. Mclean, M. Nalos

. 2021 ; 49 (9) : 1493-1503. [pub] 20210901

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025002

OBJECTIVES: To examine the effect of premorbid β-blocker exposure on mortality and organ dysfunction in sepsis. DESIGN: Retrospective observational study. SETTING: ICUs in Australia, the Czech Republic, and the United States. PATIENTS: Total of 4,086 critical care patients above 18 years old with sepsis between January 2014 and December 2018. INTERVENTION: Premorbid beta-blocker exposure. MEASUREMENTS AND MAIN RESULTS: One thousand five hundred fifty-six patients (38%) with premorbid β-blocker exposure were identified. Overall ICU mortality rate was 15.1%. In adjusted models, premorbid β-blocker exposure was associated with decreased ICU (adjusted odds ratio, 0.80; 95% CI, 0.66-0.97; p = 0.025) and hospital (adjusted odds ratio, 0.83; 95% CI, 0.71-0.99; p = 0.033) mortality. The risk reduction in ICU mortality of 16% was significant (hazard ratio, 0.84, 95% CI, 0.71-0.99; p = 0.037). In particular, exposure to noncardioselective β-blocker before septic episode was associated with decreased mortality. Sequential Organ Failure Assessment score analysis showed that premorbid β-blocker exposure had potential benefits in reducing respiratory and neurologic dysfunction. CONCLUSIONS: This study suggests that β-blocker exposure prior to sepsis, especially to noncardioselective β blockers, may be associated with better outcome. The findings suggest prospective evaluation of β-blocker use in the management of sepsis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025002
003      
CZ-PrNML
005      
20211026134218.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/CCM.0000000000005034 $2 doi
035    __
$a (PubMed)33938711
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tan, Kaiquan $u Nepean Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, Australia
245    10
$a Association Between Premorbid Beta-Blocker Exposure and Sepsis Outcomes-The Beta-Blockers in European and Australian/American Septic Patients (BEAST) Study / $c K. Tan, M. Harazim, A. Simpson, YC. Tan, G. Gunawan, KP. Robledo, C. Whitehead, B. Tang, A. Mclean, M. Nalos
520    9_
$a OBJECTIVES: To examine the effect of premorbid β-blocker exposure on mortality and organ dysfunction in sepsis. DESIGN: Retrospective observational study. SETTING: ICUs in Australia, the Czech Republic, and the United States. PATIENTS: Total of 4,086 critical care patients above 18 years old with sepsis between January 2014 and December 2018. INTERVENTION: Premorbid beta-blocker exposure. MEASUREMENTS AND MAIN RESULTS: One thousand five hundred fifty-six patients (38%) with premorbid β-blocker exposure were identified. Overall ICU mortality rate was 15.1%. In adjusted models, premorbid β-blocker exposure was associated with decreased ICU (adjusted odds ratio, 0.80; 95% CI, 0.66-0.97; p = 0.025) and hospital (adjusted odds ratio, 0.83; 95% CI, 0.71-0.99; p = 0.033) mortality. The risk reduction in ICU mortality of 16% was significant (hazard ratio, 0.84, 95% CI, 0.71-0.99; p = 0.037). In particular, exposure to noncardioselective β-blocker before septic episode was associated with decreased mortality. Sequential Organ Failure Assessment score analysis showed that premorbid β-blocker exposure had potential benefits in reducing respiratory and neurologic dysfunction. CONCLUSIONS: This study suggests that β-blocker exposure prior to sepsis, especially to noncardioselective β blockers, may be associated with better outcome. The findings suggest prospective evaluation of β-blocker use in the management of sepsis.
650    _2
$a APACHE $7 D018806
650    _2
$a mladiství $7 D000293
650    _2
$a beta blokátory $x škodlivé účinky $x farmakologie $7 D000319
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a odds ratio $7 D016017
650    _2
$a hodnocení výsledků zdravotní péče $x metody $x statistika a číselné údaje $7 D017063
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a sepse $x farmakoterapie $x patofyziologie $7 D018805
651    _2
$a Česká republika $7 D018153
651    _2
$a Nový Jižní Wales $7 D009517
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Harazim, Martin $u Medical Intensive Care Unit, University Hospital and Biomedicine Centre, Pilsen, Charles University Prague, Prague, Czech Republic
700    1_
$a Simpson, Andrew $u Department of Intensive Care Medicine, Nepean Hospital, Kingswood, NSW, Australia
700    1_
$a Tan, Yi Chern $u Department of Computer Science, Yale University, New Haven, CT
700    1_
$a Gunawan, Gunawan $u Medistra Hospital, Jakarta, Indonesia
700    1_
$a Robledo, Kristy P $u NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia
700    1_
$a Whitehead, Christina $u Department of Intensive Care Medicine, Nepean Hospital, Kingswood, NSW, Australia
700    1_
$a Tang, Benjamin $u Nepean Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, Australia $u Centre for immunology and allergy research, Westmead Millennium Institute, Westmead, NSW, Australia
700    1_
$a Mclean, Anthony $u Nepean Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, Australia $u Department of Intensive Care Medicine, Nepean Hospital, Kingswood, NSW, Australia
700    1_
$a Nalos, Marek $u Nepean Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, Australia $u Medical Intensive Care Unit, University Hospital and Biomedicine Centre, Pilsen, Charles University Prague, Prague, Czech Republic $u Department of Intensive Care Medicine, Nepean Hospital, Kingswood, NSW, Australia $u Department of Computer Science, Yale University, New Haven, CT $u Medistra Hospital, Jakarta, Indonesia $u NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia $u Centre for immunology and allergy research, Westmead Millennium Institute, Westmead, NSW, Australia
773    0_
$w MED00009514 $t Critical care medicine $x 1530-0293 $g Roč. 49, č. 9 (2021), s. 1493-1503
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33938711 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134224 $b ABA008
999    __
$a ok $b bmc $g 1714171 $s 1145509
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 49 $c 9 $d 1493-1503 $e 20210901 $i 1530-0293 $m Critical care medicine $n Crit Care Med $x MED00009514
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace